CancersAdenocarcinoma of the gastroesophageal junctionEsophagusMetastatic gastricCarcinomaCarcinomasReflux diseaseChemotherapy2023Esophageal CancerGastric mucosaPatients with unresectableEsophagogastric JunctionCapecitabineStomachPlaceboAnatomicalTypicallyTreatmentForecastAnalysisReportEsophageal adenocarcinomaGastric and gastroesophageal junction cancerPatientsCancerTumorMucosaMetastaticResectionGastro-esophageSurgicalPhaseSurvivalPresent
Cancers7
- The high morbidity and mortality of patients with esophageal (E) and gastro-esophageal junction (GEJ) cancers, warrants new pre-clinical models for drug testing. (escholarship.org)
- Gastric and gastroesophageal cancers are a global problem and there have been advances in treatment in the past few years. (facs.org)
- One of the most prevalent cancers globally is GEJ (gastric and gastroesophageal junction) cancer. (olympusresearchglobal.com)
- Despite the fact that immunotherapy has been hailed as a success in oncology over the past ten years, the response rates in gastric and gastroesophageal cancers have been very low when compared to other malignancies, which has limited its acceptance and mostly restricted it to second-line therapy. (olympusresearchglobal.com)
- These novel findings remain to be replicated in larger studies and with the addition of serological determinations to better understand their biological significance in the context of esophageal and gastroesophageal junction cancers. (biomedcentral.com)
- Health care professionals are often stymied in how to treat patients with gastric or gastroesophageal junction (GEJ) cancers who become resistant to first-line therapy or who cannot tolerate treatment due to toxicities. (gastro.org)
- Guideline] NCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Junction Cancers. (medscape.com)
Adenocarcinoma of the gastroesophageal junction3
- According to the above explanations, we tried to prepare and formulate a chemotherapeutic drug (gold nanoparticles in aqueous medium using Rhus coriaria L. fruit aqueous extract) for the treatment of several types of esophageal cancer including human esophageal squamous cell carcinoma, human Caucasian esophageal carcinoma, adenocarcinoma of the gastroesophageal junction, and distal esophageal adenocarcinoma. (ac.ir)
- To survey the cytotoxicity and anti-esophageal cancer effects of HAuCl4, R. coriaria aqueous extract, and gold nanoparticles, dye compound 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromidefor (MTT) assay was used on the human esophageal squamous cell carcinoma (KYSE-270), human Caucasian esophageal carcinoma (OE33), adenocarcinoma of the gastroesophageal junction (ESO26), and distal esophageal adenocarcinoma (FLO-1) cell lines. (ac.ir)
- After approving the above results in the clinical trial studies, these gold nanoparticles can be used as a chemotherapeutic drug for the treatment of several types of esophageal cancer such as human esophageal squamous cell carcinoma, human Caucasian esophageal carcinoma, adenocarcinoma of the gastroesophageal junction, and distal esophageal adenocarcinoma. (ac.ir)
Esophagus6
- Gastroesophageal junction adenocarcinoma is a type of cancer arising from the glandular cells that line the inner surface of the esophagus. (imarcgroup.com)
- The increasing cases of chronic acid reflux, which causes long-lasting inflammation and damage to the lining of the esophagus, are primarily driving the gastroesophageal junction adenocarcinoma market. (imarcgroup.com)
- 1 Gastroesophageal junction (GEJ) adenocarcinoma occurs at the junction of the esophagus and stomach. (cancerfax.com)
- Tumor histology, gastric mucosa histology and gastroesophageal reflux history are the three main factors that determine the origin of GEJ adenocarcinoma from the esophagus or stomach. (cancerfax.com)
- The Society of Thoracic Surgeons practice guidelines on the role of multimodality treatment for cancer of the esophagus and gastroesophageal junction. (medscape.com)
- Gastroesophageal junction adenocarcinoma, a form of cancer that is located in the region where the esophagus joins the stomach, is also rare, but equally lethal. (southcarolinablues.com)
Metastatic gastric11
- Olympus Research Global's (ORG) "Metastatic Gastric and gastroesophageal junction (GEJ)- Market Insights, Epidemiology, Industry trends & Market Forecast-2034" report provides an overview of the disease and market size of Metastatic Gastric and gastroesophageal junction (GEJ) for the seven major markets i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. (olympusresearchglobal.com)
- The Report covers the overview, treatment practice, and Metastatic Gastric and gastroesophageal junction (GEJ) forecasted epidemiology from 2021 to 2034 segmented by the seven major markets. (olympusresearchglobal.com)
- This segment of the Metastatic Gastric and gastroesophageal junction (GEJ) report encloses a detailed analysis of marketed drugs and late-stage pipeline drugs. (olympusresearchglobal.com)
- The incidence of Metastatic Gastric and gastroesophageal junction (GEJ) is increasing at a significant rate and thus has led to the growing need for effective drugs in recent years. (olympusresearchglobal.com)
- Factors such as the increasing prevalence, advanced diagnostic technologies, increased R&D, and growing public and private sector initiatives to increase awareness about Metastatic Gastric and gastroesophageal junction (GEJ) are expected to fuel the growth of the global market. (olympusresearchglobal.com)
- Effects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS). (bvsalud.org)
- In the phase III TAGS trial, trifluridine /tipiracil showed survival benefit versus placebo in patients with metastatic gastric/ gastroesophageal junction cancer and ≥ 2 prior chemotherapies . (bvsalud.org)
- In TAGS, third- or later-line trifluridine /tipiracil treatment demonstrated overall and progression-free survival and functioning benefits versus placebo and a consistent safety profile in patients with metastatic gastric/ gastroesophageal junction cancer , regardless of prior treatment type. (bvsalud.org)
- The results from KEYNOTE-859 show the potential of Keytruda plus chemotherapy to improve survival beyond chemotherapy alone for patients with HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, regardless of PD-L1 expression," said Dr. Eliav Barr, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. (medthority.com)
- Zev Wainberg, MD, of the University of California, Los Angeles Medical Center, discusses preliminary data on the safety and efficacy of TTX-030, an anti-CD39 antibody, in combination with budigalimab and FOLFOX for the first-line treatment of locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. (ascopost.com)
- Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial. (helsedirektoratet.no)
Carcinoma1
- Carcinoma of the cardia: carcinoma of the gastroesophageal junction-classification, pathology and extent of resection. (wikipedia.org)
Carcinomas2
- Durvalumab is under clinical development by AstraZeneca and currently in Phase III for Gastroesophageal (GE) Junction Carcinomas. (pharmaceutical-technology.com)
- According to GlobalData, Phase III drugs for Gastroesophageal (GE) Junction Carcinomas have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. (pharmaceutical-technology.com)
Reflux disease4
- Endoscopic photograph of an inflammatory poly in a 15 yo with chronic gastroesophageal reflux disease. (naspghan.org)
- Patients with confirmed nonerosive gastroesophageal reflux disease (GERD) are not at greater risk for esophageal cancer compared with the general population and are unlikely to need additional endoscopic monitoring for cancer, new research suggests. (medscape.com)
- The changing progression of gastroesophageal reflux disease, the complex influence of proton pump inhibitors, and the potential for a range of underlying pathophysiological causes requires a more comprehensive diagnostic perspective," they conclude. (medscape.com)
- Our aim was to evaluate the clinicopathological significance of the lesion by relating its presence to various histological and clinical and/or endoscopic features indicating gastroesophageal reflux disease (GERD). (who.int)
Chemotherapy7
- The SPOTLIGHT study, presented at ASCO GI, indicates promising effects of combining Zolbetuximab with mFOLFOX6 chemotherapy as first-line treatment for people with advanced gastroesophageal junction adenocarcinoma resistant to surgery. (bpno.se)
- Read research from the March 2023 session of the ASCO Plenary Series, which highlights a study evaluating a new targeted therapy drug given in combination with chemotherapy for people with advanced gastric or gastroesophageal junction cancer. (cancer.net)
- In advanced adenocarcinoma of GC, gastroesophageal junction cancer (GEJC) and esophageal cancer (EC), the combination of nivolumab and chemotherapy in first-line therapy improves overall survival (OS) in PD-L1 (programmed cell death protein 1)-positive patients with approval in Europe (PD-L1 CPS (combined positivity score) ≥ 5), USA and Taiwan (CHECKMATE-649) and pembrolizumab plus chemotherapy for GEJC and EC in Europe (CPS ≥ 10) and the USA (KEYNOTE-590). (mdpi.com)
- The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI. (helsedirektoratet.no)
- Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. (helsedirektoratet.no)
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. (helsedirektoratet.no)
- Ramucirumab is considered MEDICALLY NECESSARY as a single agent or in combination with paclitaxel for the treatment of individuals with advanced (non-resectable) or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma with disease progression that occurs during or after fluoropyrimidine- or platinum-containing chemotherapy. (southcarolinablues.com)
20231
- The 7 major gastroesophageal junction adenocarcinoma markets are expected to exhibit a CAGR of 14.4% during 2023-2033. (imarcgroup.com)
Esophageal Cancer1
- Here, we report the prevalence of mucosal human papillomavirus (HPV) and of Helicobacter pylori ( H. pylori ) detection in endoscopy-obtained esophageal and gastroesophageal junction biopsies and in oral cell specimens taken at the time of esophageal cancer diagnosis in a case-control study in Addis Ababa, Ethiopia. (biomedcentral.com)
Gastric mucosa1
- In case of the tumor being located in the gastro-esophageal junction, a 2-cm distal margin of clinically uninvolved gastric mucosa is sufficient. (cancercentrum.se)
Patients with unresectable1
- As reported in the Journal of Clinical Oncology by Maron et al, a retrospective study found that use of EGFR inhibitor therapy was associated with benefit in patients with unresectable or metastatic EGFR-amplified gastroesophageal adenocarcinoma. (ascopost.com)
Esophagogastric Junction3
- The Siewert-Stein classification (often called the Siewert classification in less precise shorthand reference) is a system of anatomical classification used for adenocarcinomas of the esophagogastric junction. (wikipedia.org)
- Mönig, Stefan P. (2017), "Siewert Classification of Adenocarcinoma of the Esophagogastric Junction: Still in or Already Out? (wikipedia.org)
- Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. (helsedirektoratet.no)
Capecitabine1
- Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. (helsedirektoratet.no)
Stomach1
- Histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction. (who.int)
Placebo1
- 1 ] Therefore, CheckMate 577 (CM577), a global, randomized, double-blind, placebo-controlled phase 3 trial, has explored the role of an immune checkpoint inhibitor (ICPI), Nivolumab as adjuvant therapy in patients with esophageal or gastroesophageal junction (GEJ) cancer who did not achieve a PCR. (thieme-connect.com)
Anatomical1
- Introduction: Ligamentous attachments maintain the normal anatomical position of the gastroesophageal (GE) junction. (sages.org)
Typically1
- The diagnosis of gastroesophageal junction adenocarcinoma typically involves a combination of the patient's clinical features, medical history, and physical examination. (imarcgroup.com)
Treatment2
- According to the report the United States has the largest patient pool for gastroesophageal junction adenocarcinoma and also represents the largest market for its treatment. (imarcgroup.com)
- They have been studied in the first- and second-line settings for the treatment of gastroesophageal cancer. (olympusresearchglobal.com)
Forecast1
- Additionally, the emerging popularity of cryotherapy owing to its various advantages, like smaller incisions, reduced risk of complications, faster recovery times, etc., is expected to drive the gastroesophageal junction adenocarcinoma market during the forecast period. (imarcgroup.com)
Analysis1
- IMARC Group's new report provides an exhaustive analysis of the gastroesophageal junction adenocarcinoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. (imarcgroup.com)
Report1
- This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the gastroesophageal junction adenocarcinoma market in any manner. (imarcgroup.com)
Esophageal adenocarcinoma4
- Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): interim results of nivolumab plus chemotherapy (N+C) versus (C) from CheckMate 649. (oncpracticemanagement.com)
- The results of a population-based, case-controlled study from Sweden strongly suggest that symptomatic gastroesophageal reflux is a risk factor for esophageal adenocarcinoma. (cancer.gov)
- Note: subjects with esophageal adenocarcinoma and adenocarcinoma of gastroesophageal junction (GEJ) are excluded. (bcan.org)
- I was diagnosed with Stage IV esophageal adenocarcinoma at the Gastro-esophageal junction (GEJ) 6 weeks ago. (cancer.org)
Gastric and gastroesophageal junction cancer3
- Leap Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation for DKN-01 for the treatment of gastric and gastroesophageal junction cancer. (pharmaceutical-business-review.com)
- Orphan Drug Designation for DKN-01 in gastric and gastroesophageal junction cancer is another significant milestone in our DKN-01 development program and underscores the need for new treatment options for these indications," said Douglas E. Onsi, President and Chief Executive Officer of Leap. (pharmaceutical-business-review.com)
- US immuno-oncology company Leap Therapeutics has been granted orphan drug designation for DKN-01 from the US Food and Drug Administration (FDA) for the treatment of gastric and gastroesophageal junction cancer. (pharmanewsdaily.com)
Patients11
- Officials with the FDA have approved nivolumab (Opdivo) as the first and only immunotherapy indicated for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT). (pharmacytimes.com)
- Among 796 patients with esophageal or gastroesophageal junction adenocarcinoma who underwent curative resection, surgical pathology reports were reviewed, and suspected ASC was confirmed utilizing p63 and CK5/6 immunostaining. (nih.gov)
- Site initiation activities are now underway for the Company's combination study of DKN-01 plus tislelizumab, BeiGene, Ltd.'s anti-PD-1 antibody, in patients with gastric or gastroesophageal junction cancer with dosing of the first patients expected in the third quarter of 2020. (pharmaceutical-business-review.com)
- Unfortunately, 30% of EAC patients present with gastroesophageal junction adenocarcinomas (GEJAC) and lack premalignant Barrett's metaplasia, limiting this early detection strategy. (oncotarget.com)
- Leap Therapeutics said that it is carrying out site initiation activities for its combination study of DKN-01 plus BeiGene's anti-PD-1 antibody tislelizumab in patients having gastric or gastroesophageal junction cancer with dosing of the first patients likely to take place in Q3 2020. (pharmanewsdaily.com)
- Patients with advanced gastric, esophageal, or gastroesophageal junction cancer (GEJC) experience a decrease in health status and overall health-related quality of life (HRQOL) due to an increase in cancer-related symptoms and from the side effects of treatment. (oncpracticemanagement.com)
- Since contrast radiography and endoscopy frequently fail to differentiate these 2 entities, patients with a presumed diagnosis of achalasia but who have a shorter duration of symptoms, greater weight loss, and a more advanced age and who are referred for minimally invasive surgery should undergo additional imaging studies, including endoscopic ultrasound and computed tomography with fine cuts of the gastroesophageal junction, to rule out cancer. (medscape.com)
- A phase 3 trial shows that zolbetuximab improved survival in patients with advanced gastric or gastroesophageal junction cancer. (curetoday.com)
- Only about half of patients relate symptoms of chronic gastroesophageal reflux. (spiritindia.com)
- After the procedure, smooth passage of the endoscope through the gastroesophageal junction was observed in all patients. (lww.com)
- A combination VEGFR-2 inhibitor plus an antiâ€"PD-L1 agent demonstrated antitumor activity in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma. (pharmacytimes.com)
Cancer3
- IDX-1197 (NOV1401) is under development for the treatment of solid tumors including high-grade serious ovarian cancer, breast cancer, gastroesophageal junction, endometrial cancer, fallopian tube cancer, uterine cancer, gastric cancer and pancreatic cancer. (globaldata.com)
- Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061 [published correction appears in Gastric Cancer . (oncpracticemanagement.com)
- 7. Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial. (nih.gov)
Tumor1
- See the KEYTRUDA® product label for expression cutoff values guiding therapy in specific clinical circumstances.Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaPD-L1 protein expression in gastric or GEJ adenocarcinoma is determined by using Combined Positive Score (CPS), which is the number of PD-L1 staining cells (tumor cells, lymphocytes, macrophages) divided by the total number of viable tumor cells, multiplied by 100. (fda.gov)
Mucosa1
- tEAC) collected above the gastroesophageal junction with 70 GEJACs, 8 normal esophageal and 5 normal gastric mucosa samples. (oncotarget.com)
Metastatic2
- The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. (nih.gov)
- Maintenance chemotherapy in metastatic gastro-esophageal junction and gastric tumors. (chop.edu)
Resection1
- Carcinoma of the cardia: carcinoma of the gastroesophageal junction-classification, pathology and extent of resection. (wikipedia.org)
Gastro-esophage1
- Ideally, the tip should be at least 10 cm beyond the gastro-esophageal junction 1 . (radiopaedia.org)
Surgical1
- Although the incidence of gastroesophageal junction (GEJ) adenocarcinoma has been increasing worldwide, no standardized surgical strategy for its treatment has been established. (elsevierpure.com)
Phase1
- The purpose of this phase II study was to evaluate the efficacy and safety of cetuximab combined with FOLFIRI as a first-line treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. (nih.gov)
Survival1
- 16. Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. (nih.gov)
Present1
- In the present study, the expressions of PD-L1 and Her2neu were analyzed in relation to clinicopathological parameters including p53 in gastric and gastroesophageal junction adenocarcinoma. (nih.gov)